Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone011-353-1772-2100
Debt
Current Ratio1.94
Quick Ratio1.86
Price-To-Earnings
Sales & Book Value
Annual Sales$1.06 billion
Price / Sales3.52
Price / Cash Flow7.19
Price / Book3.66
Profitability
Net Income$-410,520,000.00
Net Margins-18.70%
Return on Assets6.09%
Miscellaneous
Employees1,010
OptionableOptionable
Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Pharma's stock symbol?
Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."
How will Horizon Pharma's stock buyback program work?
Horizon Pharma announced that its board has initiated a share repurchase plan on Sunday, June 4th 2017, which authorizes the company to repurchase 1,000% of outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board believes its stock is undervalued.
How were Horizon Pharma's earnings last quarter?
Horizon Pharma PLC (NASDAQ:HZNP) posted its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported $0.65 EPS for the quarter, beating the Zacks' consensus estimate of $0.50 by $0.15. The biopharmaceutical company earned $325.30 million during the quarter, compared to the consensus estimate of $311.84 million. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. Horizon Pharma's revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 EPS. View Horizon Pharma's Earnings History.
When is Horizon Pharma's next earnings date?
What guidance has Horizon Pharma issued on next quarter's earnings?
Horizon Pharma updated its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.17-1.2 billion, compared to the consensus revenue estimate of $1.18 billion.
What price target have analysts set for HZNP?
12 brokerages have issued 12 month target prices for Horizon Pharma's stock. Their forecasts range from $18.00 to $35.00. On average, they expect Horizon Pharma's share price to reach $23.7273 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Price Targets for Horizon Pharma.
What is the consensus analysts' recommendation for Horizon Pharma?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Pharma in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Pharma.
What are Wall Street analysts saying about Horizon Pharma stock?
Here are some recent quotes from research analysts about Horizon Pharma stock:
- 1. Mizuho analysts commented, "We reiterate our Buy rating on Krystexxa momentum and upcoming teprotumumab Phase III data (expected 2Q:19)." (11/7/2018)
- 2. Cantor Fitzgerald analysts commented, ". We are raising our 12-month PT for HZNP shares to $23 from $21. The increase in our PT is driven by multiple expansion. We think this is deserved because continued solid execution from the management team underscores our belief that the peak sales potential of HZNP’s orphan/rare disease as well as rheumatology businesses are underappreciated." (10/18/2018)
- 3. Cowen Inc analysts commented, "Sarepta (SRPT) reported 2Q18 sales/earnings and provided a business update on 8/8. Exondys51 sales of $74M topped our expectations (see below) by 5%, and accelerated sequentially in 2Q18, after a slight dip in 1Q18. However, SRPT kept its FY18 guidance unchanged. OPEX is increasing faster than expectations, with FY18E non-GAAP OPEX potentially >2X 2016 levels of $198M. With sales growth starting to slow to high single digits Q/Q, focus is increasingly turning to the early/mid-stage pipeline to deliver commercial products in the near term. We continue to believe that gene therapy projects will take a minimum of 3-5 years to get to market and the exon- skipping agents (53 & 45) on-market by 2020. We stay neutral on the name." (8/9/2018)
- 4. According to Zacks Investment Research, "Horizon Pharma’s orphan and rheumatology business units witnessed strong growth. We expect Krystexxa, Ravicti and Actimmune to drive further growth. The acquisition of teprotumumab has further diversified the company’s portfolio. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. In June 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in Europe, the Middle East and Africa to Chiesi Farmaceutici S.p.A. to focus on higher return businesses. Shares of the company have outperformed the industry so far this year." (7/17/2018)
Has Horizon Pharma been receiving favorable news coverage?
News coverage about HZNP stock has trended positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Horizon Pharma earned a coverage optimism score of 2.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the stock's share price in the immediate future.
Who are some of Horizon Pharma's key competitors?
Some companies that are related to Horizon Pharma include Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), SAGE Therapeutics (SAGE) and Amarin (AMRN).
Who are Horizon Pharma's key executives?
Horizon Pharma's management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
- Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 49)
- Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 54)
Who are Horizon Pharma's major shareholders?
Horizon Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sheets Smith Wealth Management (0.01%). Company insiders that own Horizon Pharma stock include Brian K Beeler, Geoffrey M Curtis, Michael G Grey, Robert Carey and Timothy P Walbert. View Institutional Ownership Trends for Horizon Pharma.
Which major investors are buying Horizon Pharma stock?
How do I buy shares of Horizon Pharma?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Pharma's stock price today?
One share of HZNP stock can currently be purchased for approximately $22.15.
How big of a company is Horizon Pharma?
Horizon Pharma has a market capitalization of $3.68 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe.
What is Horizon Pharma's official website?
How can I contact Horizon Pharma?
Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Pharma (NASDAQ HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
